Gene therapy using extracellular vesicles loaded with miRNA derived from Bone Marrow Mesenchymal Stem Cells is a cell-free medication delivery method used in a variety of diseases

Moataz Dowaidar

DOI: https://doi.org/10.31219/osf.io/3znvw

2021-06-10

Abstract:The majority of neuro cancer research focuses on glioblastoma. BMSC-loaded miR-146b, miR-124a, miR-584, miR-133b, and miR-199a cause glioblastoma cell death by inducing apoptosis. These cancers have also been studied, but the number of studies is less than that of glioblastoma.Research into mental illness, renal injury, fibrosis, SCI, and stroke takes precedence over cancer research.MI is a well-researched disease model. miR-21, miR-132, miR-21a-5p, miR-125b, miR-214, miR-301, and miR-133 demonstrate cardioprotective properties according to these studies. miR-199a-5p, miR-486, miR-10, and miR-199a-3p suppressed the ER stress proteins and apoptotic proteins, reducing renal cell death from I/R. The use of miRNA-loaded BMSC EVs in the aforementioned fibrosis models was also proven. The research suggests that BMSC-derived EVs loaded with the aforementioned microRNAs have beneficial effects on ischemic and hemorrhagic stroke models. In SCI models, miR-133b, miR-29b, miR-21, miR-25, and miR-544 have been found to assist neural regeneration. Comparing these studies is difficult due to their complexity. These variables can be broken down as follows: Some studies only in vitro or in vivo studies, different cell lines or in vivo disease models were used in the studies, there were insufficient studies in some disease models, and different miRNAs determined by bioinformatics methods were used in each study. miRNA-derived BMSC-derived EVs are cell-free medication delivery approaches in a range of illness types. The technique employs bioinformatics analysis to find miRNAs that are downregulated in a disease model and/or miRNAs that target increased proteins in a particular signaling pathway. Electrical vehicles offer several benefits over cell-based transplantation and non-biological medication delivery technologies. To study the efficacy of this approach, there are no clinical trial investigations. A scarcity of immunogenicity and toxicity studies in these studies could hold back this method from going into clinical trials. It may be because EVs aren't intended for certain tissues or organs. Various strategies for EV membrane protein alterations and the creation of decorated EVs for cell-specific targeting have been devised. This is just a subset of the approaches available for targeted drug delivery. RVG/Lamp2b decorated EVs for nerve cell targeting can be mentioned. Additionally, superparamagnetic iron oxide nanoparticle modification of EV surfaces, chemical ligand assembly on exosomal surfaces, and pH gradient/surface charge-driven targeting may increase the efficacy of miRNA-loaded EV applications.